Tasquinimod Combined With Immunotherapy Reduces Tumor Burden in Preclinical Lung Cancer
Researchers characterized bone marrow remodeling during lung cancer progression and found tasquinimod combined with anti-PD-L1 immunotherapy significantly reduced tumor burden ...

